Invivyd
Biologics & Biosimilars · Infectious Disease Therapeutics

Invivyd revenue, results and funding

Invivyd filed revenue of $53.4M for 2025.

Data updated Nov 20, 2026 · Back to the company report
$53.4MRevenue, 2025
−$52.5MNet income, 2025

Results by year

YearRevenueNet incomeTotal assetsLANG_CR_S_M_TAX_EXPENSELANG_CR_S_M_BUYBACKSLANG_CR_S_M_CAPEXLANG_CR_S_M_SBCLANG_CR_S_M_RNDLANG_CR_S_M_OPERATING_INCOMELANG_CR_S_M_CASH
2025$53.4M−$52.5M$276.9M$0–$155k$11.6M$38.3M−$55.6M$226.7M
2024$25.4M−$169.9M$129.5M$0$0$140k$19.8M$137.3M−$176.9M$69.3M
2023$0−$198.6M$229.2M$0$1k$615k$18.7M$158.7M−$212.8M$200.6M
2022–−$241.3M$383.2M$0$4k$1.7M$21.6M$179.2M−$248M$92.1M
2021–−$226.8M$620.1M$0$0$84k$17.8M$182.9M−$226.9M$542.2M
2020–−$38.7M$117.4M––––––$115M
Sources: SEC

How to cite

Invivyd, Financials. Alion, Nov 20, 2026. https://alion.io/company/invivyd/financials

.json · .md · CC BY-SA 4.0